Therapeutic Antibody Against Phosphorylcholine Preserves Coronary Function and Attenuates Vascular 18 F-FDG Uptake in Atherosclerotic Mice

This study showed that treatment with a therapeutic monoclonal immunoglobulin-G1 antibody against phosphorylcholine on oxidized phospholipids preserves coronary flow reserve and attenuates atherosclerotic inflammation as determined by the uptake of F-fluorodeoxyglucose in atherosclerotic mice. The n...

Full description

Saved in:
Bibliographic Details
Published in:JACC. Basic to translational science 2020-04, Vol.5 (4), p.360
Main Authors: Ståhle, Mia, Silvola, Johanna M U, Hellberg, Sanna, de Vries, Margreet, Quax, Paul H A, Kroon, Jeffrey, Rinne, Petteri, de Jong, Alwin, Liljenbäck, Heidi, Savisto, Nina, Wickman, Anna, Stroes, Erik S G, Ylä-Herttuala, Seppo, Saukko, Pekka, Abrahamsson, Tommy, Pettersson, Knut, Knuuti, Juhani, Roivainen, Anne, Saraste, Antti
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study showed that treatment with a therapeutic monoclonal immunoglobulin-G1 antibody against phosphorylcholine on oxidized phospholipids preserves coronary flow reserve and attenuates atherosclerotic inflammation as determined by the uptake of F-fluorodeoxyglucose in atherosclerotic mice. The noninvasive imaging techniques represent translational tools to assess the efficacy of phosphorylcholine-targeted therapy on coronary artery function and atherosclerosis in clinical studies.
ISSN:2452-302X